Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Beam Therapeutics (BEAM) FCF Margin (2019 - 2025)

Historic FCF Margin for Beam Therapeutics (BEAM) over the last 7 years, with Q3 2025 value amounting to 891.83%.

  • Beam Therapeutics' FCF Margin fell 2631800.0% to 891.83% in Q3 2025 from the same period last year, while for Sep 2025 it was 632.59%, marking a year-over-year decrease of 5910100.0%. This contributed to the annual value of 560.77% for FY2024, which is 5123400.0% down from last year.
  • Per Beam Therapeutics' latest filing, its FCF Margin stood at 891.83% for Q3 2025, which was down 2631800.0% from 940.07% recorded in Q2 2025.
  • In the past 5 years, Beam Therapeutics' FCF Margin ranged from a high of 2409.68% in Q1 2022 and a low of 834266.67% during Q1 2021
  • Over the past 5 years, Beam Therapeutics' median FCF Margin value was 546.13% (recorded in 2022), while the average stood at 87009.52%.
  • In the last 5 years, Beam Therapeutics' FCF Margin crashed by 2000000000bps in 2021 and then skyrocketed by 2000000000bps in 2022.
  • Quarter analysis of 5 years shows Beam Therapeutics' FCF Margin stood at 22.59% in 2021, then tumbled by -1611bps to 386.54% in 2022, then skyrocketed by 111bps to 41.58% in 2023, then tumbled by -735bps to 263.86% in 2024, then plummeted by -238bps to 891.83% in 2025.
  • Its FCF Margin stands at 891.83% for Q3 2025, versus 940.07% for Q2 2025 and 1431.71% for Q1 2025.